
Willem J Mulder, PhD
About Me
Willem Mulder, Ph.D., a biomedical engineer with a background in nanochemistry, is Professor of Radiology and Professor of Oncological Sciences at Icahn School of Medicine at Mount Sinai (ISMMS) in New York, as well as Professor of Precision Medicine at the Eindhoven University of Technology (TU/e), The Netherlands. Mulder obtained an M.Sc. in Chemistry from the Utrecht University (2001) and a Ph.D. in Biomedical Engineering from Eindhoven University of Technology (2006).
Mulder pioneered the exploitation of nanomaterials as highly tunable immunotherapeutics and molecular imaging agents. His research focuses on (nano-)immunotherapy and precision imaging in cardiovascular diseases, cancer and transplantation. Mulder established library technology, encompassing nanomaterials derived from natural lipoproteins (nanobiologics), that allows meticulously designing targeted immunotherapies. When appropriately designed, such nanobiologics can be applied to empower the immune system’s ability to fight disease, by promoting or inhibiting an immune response, by polarizing macrophage function, or by targeting myeloid cell dynamics.
Mulder has published more than 150 scientific publications in top scientific journals, including Nature Nanotechnology, Nature Reviews Drug Discovery, Nature Communications, Science Translational Medicine, Immunity, etc. His H-index is 62 and his work has been cited more than 11.000 times. Mulder is the principal investigator of multiple National Institutes of Health grants. In 2013, he received the Vidi grant, while in 2018 and the Vici grant from the Dutch Science Foundation (NWO).
Language
Position
About Me
Willem Mulder, Ph.D., a biomedical engineer with a background in nanochemistry, is Professor of Radiology and Professor of Oncological Sciences at Icahn School of Medicine at Mount Sinai (ISMMS) in New York, as well as Professor of Precision Medicine at the Eindhoven University of Technology (TU/e), The Netherlands. Mulder obtained an M.Sc. in Chemistry from the Utrecht University (2001) and a Ph.D. in Biomedical Engineering from Eindhoven University of Technology (2006).
Mulder pioneered the exploitation of nanomaterials as highly tunable immunotherapeutics and molecular imaging agents. His research focuses on (nano-)immunotherapy and precision imaging in cardiovascular diseases, cancer and transplantation. Mulder established library technology, encompassing nanomaterials derived from natural lipoproteins (nanobiologics), that allows meticulously designing targeted immunotherapies. When appropriately designed, such nanobiologics can be applied to empower the immune system’s ability to fight disease, by promoting or inhibiting an immune response, by polarizing macrophage function, or by targeting myeloid cell dynamics.
Mulder has published more than 150 scientific publications in top scientific journals, including Nature Nanotechnology, Nature Reviews Drug Discovery, Nature Communications, Science Translational Medicine, Immunity, etc. His H-index is 62 and his work has been cited more than 11.000 times. Mulder is the principal investigator of multiple National Institutes of Health grants. In 2013, he received the Vidi grant, while in 2018 and the Vici grant from the Dutch Science Foundation (NWO).
Language
Position
Education
MSc, Utrecht University
PhD, Eindhoven University of Technology
Locations
Publications
Selected Publications
- Targeting mTOR in myeloid cells prevents infection-associated inflammation. Yohana C. Toner, Jazz Munitz, Geoffrey Prevot, Judit Morla-Folch, William Wang, Yuri van Elsas, Bram Priem, Jeroen Deckers, Tom Anbergen, Thijs J. Beldman, Eliane E.S. Brechbühl, Muhammed D. Aksu, Athanasios Ziogas, Sebastian A. Sarlea, Mumin Ozturk, Zhenhua Zhang, Wenchao Li, Yang Li, Alexander Maier, Jessica C. Fernandes, Glenn A.O. Cremers, Bas van Genabeek, Joost H.C.M. Kreijtz, Esther Lutgens, Niels P. Riksen, Henk M. Janssen, Serge H.M. Söntjens, Freek J.M. Hoeben, Ewelina Kluza, Gagandeep Singh, Evangelos J. Giamarellos-Bourboulis, Michael Schotsaert, Raphaël Duivenvoorden, Roy van der Meel, Leo A.B. Joosten, Lei Cai, Ryan E. Temel, Zahi A. Fayad, Musa M. Mhlanga, Mandy M.T. van Leent, Abraham J.P. Teunissen, Mihai G. Netea, Willem J.M. Mulder. iScience
- Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Stijn R.J. Hofstraat, Tom Anbergen, Robby Zwolsman, Jeroen Deckers, Yuri van Elsas, Mirre M. Trines, Iris Versteeg, Daniek Hoorn, Gijs W.B. Ros, Branca M. Bartelet, Merel M.A. Hendrikx, Youssef B. Darwish, Teun Kleuskens, Francisca Borges, Rianne J.F. Maas, Lars M. Verhalle, Willem Tielemans, Pieter Vader, Olivier G. de Jong, Tommaso Tabaglio, Dave Keng Boon Wee, Abraham J.P. Teunissen, Eliane Brechbühl, Henk M. Janssen, P. Michel Fransen, Anne de Dreu, David P. Schrijver, Bram Priem, Yohana C. Toner, Thijs J. Beldman, Mihai G. Netea, Willem J.M. Mulder, Ewelina Kluza, Roy van der Meel. Nature Nanotechnology
- A cis-regulatory element controls expression of histone deacetylase 9 to fine-tune inflammasome-dependent chronic inflammation in atherosclerosis. Yaw Asare, Guangyao Yan, Christina Schlegl, Matthias Prestel, Emiel P.C. van der Vorst, Abraham J.P. Teunissen, Arailym Aronova, Federica Tosato, Nawraa Naser, Julio Caputo, Geoffrey Prevot, Anthony Azzun, Benedikt Wefers, Wolfgang Wurst, Melanie Schneider, Ignasi Forne, Kiril Bidzhekov, Ronald Naumann, Sander W. van der Laan, Markus Brandhofer, Jiayu Cao, Stefan Roth, Rainer Malik, Steffen Tiedt, Willem J.M. Mulder, Axel Imhof, Arthur Liesz, Christian Weber, Jürgen Bernhagen, Martin Dichgans. Immunity